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Sir,
In the September 2007 issue of the Journal of the
Formosan Medical Association, Lin et al highlighted
an important point that is well described but less
well recognized in clinical practice.1 Indeed, they
have categorically emphasized the role of met-
formin and vitamin B12 deficiency as the plausible
cause of the deep vein thrombosis in their patient,
although the patient was proven to have a ho-
mozygous C677T mutation of the MTHFR gene
which seemed to have been the cause of the hy-
perhomocysteinemia.1 This conclusion based on
one case report is a hypothesis that has to be in-
terpreted cautiously, given the lack of definitive
evidence to support this notion in the literature.2–4
Recent data have suggested that the evidence
to support the role of metformin therapy in af-
fecting homocysteine levels is insufficient. For
example, homocysteine levels were unaffected 
by metformin treatment in pregnant and non-
pregnant women with polycystic ovarian syn-
drome.2 A previous study from Thailand suggested
that although metformin may have caused low vi-
tamin B12 levels, there were no significant changes
to homocysteine levels.3 It has also been demon-
strated that other dietary factors such as fruit and
vegetable consumption in diabetic patients are
strong independent determinants of homocysteine
levels.4
We are aware of only one large randomized
controlled trial over a period of 16 weeks that has
demonstrated metformin-related B12 deficiency
and a modest rise in homocysteine levels, the
clinical significance of which remains unknown.5
A much smaller study over a duration of 6 months
showed that the effect of metformin therapy on
homocysteine levels, if any, is likely to be small.6
Interestingly, it has recently been reported that
metformin increased levels of homocysteine and
rosiglitazone conversely decreased homocysteine
levels over a 6-week period in diabetic subjects,
the clinical significance of which again remains
unknown.7
It is therefore important to remember that 
association does not mean causation and a large
number of diabetic patients are on metformin
therapy without significant problems. The clinical
implications and exact mechanisms of metformin-
related B12 deficiency remains contentious in the
absence of large randomized controlled trials over
longer time intervals,2–7 hence the need for re-
minding clinicians of the caveats to be aware of
within the large scheme of things in people with
diabetes mellitus.
In order to inform the debate on this subject,
further studies involving a far greater number of
patients over a much longer time period is war-
ranted, especially when other plausible causes such
as hypochlorhydria could explain the mecha-
nism.8,9 However, such anecdotal case reports are
helpful for signal generation and help to remind
clinicians of a potential side effect with metformin
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therapy that is less commonly perceived in routine
daily clinical practice.
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